title: Effects of doxorubicin on myocardial expression of apolipoprotein-B.
abstract: OBJECTIVE
  Doxorubicin (DOX) is an effective antitumour agent against a variety of human malignancies but is associated with deleterious side effects, including myocardial damage and heart failure. Myocardial apoB-containing lipoprotein (apoB) is upregulated post myocardial infarction and has been shown to be cardioprotective in this setting by unloading excessive lipid. The aim of this study was to investigate whether apoB expression is increased also in DOX-induced heart failure and whether apoB overexpression protects the heart in DOX-induced myocardial injury.
  
  
  METHODS
  Cardiac function and energy metabolism was studied in mice and rats 24 hours after intraperitoneally administered DOX.
  
  
  RESULTS
  We found that the content of apoB was decreased in rat myocardium 24 hours after DOX injection. In contrast, apoB content was increased in the infarcted myocardium of rats 24 hours post ischemia-reperfusion. Moreover, transgenic mice overexpressing apoB had better cardiac function and lower intracellular lipid accumulation compared to wild type mice 24 hours post DOX.
  
  
  CONCLUSIONS
  Our findings indicate that depression of the myocardial apoB system may contribute to DOX-induced cardiac injury and that overexpression of apoB is protective, not only in ischemically damaged myocardium, but also in DOX-induced heart failure.
authors.affiliation: The Wallenberg laboratory at Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden. bjorn.redfors@wlab.gu.se
authors.forename: Bjorn
authors.initials: B
authors.lastname: Redfors
authors.forename: Yangzhen
authors.initials: Y
authors.lastname: Shao
authors.forename: Truls
authors.initials: T
authors.lastname: Råmunddal
authors.forename: Malin
authors.initials: M
authors.lastname: Lindbom
authors.forename: Margareta Scharin
authors.initials: MS
authors.lastname: Täng
authors.forename: Pia
authors.initials: P
authors.lastname: Stillemark-Billton
authors.forename: Jan
authors.initials: J
authors.lastname: Boren
authors.forename: Elmir
authors.initials: E
authors.lastname: Omerovic
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D053299:Apolipoprotein B-100 / Q000096:biosynthesis* / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D006333:Heart Failure / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000473:pathology*; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D015428:Myocardial Reperfusion Injury / Q000150:complications; D009206:Myocardium; D051381:Rats; D017207:Rats, Sprague-Dawley; D014463:Ultrasonography
chemical_list: D000903:Antibiotics, Antineoplastic; D053299:Apolipoprotein B-100; D004317:Doxorubicin